Skip to main content
HRMY
NASDAQ Life Sciences

Harmony Biosciences Posts 81-Cent Q3 EPS

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$36.499
Mkt Cap
$2.156B
52W Low
$25.902
52W High
$43.49
52W Position info
41% above low
Off High info
16% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

HRMY sits 41% above its 52-week low of $25.902.

Summary

Harmony Biosciences reported third-quarter earnings of 81 cents a share, per Dow Jones, on revenue of $268.9 million, a figure that missed estimates as profit fell on royalty charges to net income of USD 48.196 Million. That follows a record Q2 in which revenue hit $261.3 million, up 30%, and net income of $75.4 million nearly doubled year over year, so the bar was already high. The company said it is on track to achieve more than $1 billion in Wakix net revenue and announced strong multiple-ascending dose data for its orexin agonist BP-205, supporting a potential best-in-class profile. The print lands as the company works through CEO succession — COO Peter Anastasiou takes over January 1 — and awaits a ruling in the Wakix ANDA patent case against AET Pharma after October closing arguments. The pitolisant GR NDA has an April 2027 PDUFA date, keeping a second regulatory catalyst on the calendar.

At the time of this announcement, HRMY was trading at $36.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $25.90 to $43.49. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

HRMY - Latest Insights

HRMY
Nov 04, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.94
Real-time Price: $32.95 info
Change: -$2.99 (-8%) info
Market Cap: $1.935B info
HRMY
Nov 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.18
Real-time Price: $32.95 info
Change: -$3.23 (-9%) info
Market Cap: $1.935B info
HRMY
Oct 22, 2026, 3:57 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $36.03
Real-time Price: $32.95 info
Change: -$3.08 (-9%) info
Market Cap: $1.935B info
HRMY
Oct 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $32.95 info
Change: -$5.45 (-14%) info
Market Cap: $1.935B info
HRMY
Oct 12, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $40.28
Real-time Price: $32.95 info
Change: -$7.33 (-18%) info
Market Cap: $1.935B info